Private Advisor Group LLC Buys 5,745 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Private Advisor Group LLC increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 23.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 29,908 shares of the biopharmaceutical company's stock after purchasing an additional 5,745 shares during the quarter. Private Advisor Group LLC's holdings in Halozyme Therapeutics were worth $1,430,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of HALO. Heck Capital Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter worth $29,000. Venturi Wealth Management LLC acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at $69,000. Farther Finance Advisors LLC raised its position in Halozyme Therapeutics by 173.6% in the third quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company's stock valued at $93,000 after purchasing an additional 1,028 shares during the period. Centaurus Financial Inc. acquired a new position in shares of Halozyme Therapeutics during the third quarter worth about $127,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Halozyme Therapeutics in the third quarter worth about $150,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Up 2.5 %

NASDAQ:HALO traded up $1.45 during mid-day trading on Friday, reaching $59.15. The stock had a trading volume of 1,235,596 shares, compared to its average volume of 1,290,993. The stock's 50 day simple moving average is $54.53 and its two-hundred day simple moving average is $54.74. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $65.53. The company has a market capitalization of $7.28 billion, a price-to-earnings ratio of 17.24, a price-to-earnings-growth ratio of 0.42 and a beta of 1.25. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on HALO shares. HC Wainwright raised their target price on Halozyme Therapeutics from $70.00 to $72.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Benchmark reissued a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Piper Sandler raised their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. Finally, Wells Fargo & Company cut their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, Halozyme Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $62.78.

Insiders Place Their Bets

In other news, Director Jeffrey William Henderson sold 10,000 shares of the business's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the transaction, the director now owns 43,611 shares of the company's stock, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 26,697 shares of company stock valued at $1,461,001. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.